• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Salvage second transplantation in relapsed multiple myeloma.

作者信息

Dhakal Binod, D'Souza Anita, Kleman Ariel, Chhabra Saurabh, Mohan Meera, Hari Parameswaran

机构信息

Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Division of Hematology/Oncology, University of Arkansas, Little Rock, AR, USA.

出版信息

Leukemia. 2021 Apr;35(4):1214-1217. doi: 10.1038/s41375-020-1005-8. Epub 2020 Aug 4.

DOI:10.1038/s41375-020-1005-8
PMID:32747684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8020391/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81eb/8020391/3470cc7f08a5/nihms-1679783-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81eb/8020391/3470cc7f08a5/nihms-1679783-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81eb/8020391/3470cc7f08a5/nihms-1679783-f0001.jpg

相似文献

1
Salvage second transplantation in relapsed multiple myeloma.复发多发性骨髓瘤的挽救性二次移植
Leukemia. 2021 Apr;35(4):1214-1217. doi: 10.1038/s41375-020-1005-8. Epub 2020 Aug 4.
2
When to recommend a second autograft in patients with relapsed myeloma?对于复发性骨髓瘤患者，何时推荐进行第二次自体移植？
Leuk Lymphoma. 2017 Apr;58(4):781-787. doi: 10.1080/10428194.2016.1246729. Epub 2016 Nov 28.
3
Second Autologous Hematopoietic Stem Cell Transplant as Salvage Therapy for Relapsed Multiple Myeloma: A Global Treatment Option for Eligible Patients.第二次自体造血干细胞移植作为复发多发性骨髓瘤的挽救治疗：适合患者的全球治疗选择。
Acta Haematol. 2018;139(1):45-46. doi: 10.1159/000486272. Epub 2018 Jan 18.
4
Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.挽救性自体干细胞移植对复发多发性骨髓瘤的意义：日本全国性回顾性研究
Acta Haematol. 2018;139(1):35-44. doi: 10.1159/000484652. Epub 2018 Jan 17.
5
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.一种基于国际分期系统（ISS）和首次无进展生存期（PFS1）的用于接受前期自体移植后复发的骨髓瘤患者的新预后模型。
Br J Haematol. 2019 Apr;185(2):350-353. doi: 10.1111/bjh.15487. Epub 2018 Jul 9.
6
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.多发性骨髓瘤挽救性第三自体干细胞移植的结果。
Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3.
7
Autologous transplantation in multiple myeloma.多发性骨髓瘤中的自体移植
Haematologica. 2006 Sep;91(9):1157.
8
The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma.挽救性二次自体造血干细胞移植在复发性多发性骨髓瘤中的作用。
Biol Blood Marrow Transplant. 2019 Mar;25(3):e98-e107. doi: 10.1016/j.bbmt.2018.12.002. Epub 2018 Dec 8.
9
The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant.接受初始移植后维持治疗的多发性骨髓瘤患者中挽救性自体干细胞移植的疗效。
Bone Marrow Transplant. 2018 Nov;53(11):1483-1486. doi: 10.1038/s41409-018-0216-3. Epub 2018 May 24.
10
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.挽救性自体干细胞移植对复发多发性骨髓瘤患者总生存期的影响（英国血液与骨髓移植学会/英国骨髓瘤论坛骨髓瘤X复发[强化治疗]最终结果）：一项随机、开放标签的3期试验
Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7.

引用本文的文献

1
Current Treatment Strategies for Multiple Myeloma at First Relapse.多发性骨髓瘤首次复发时的当前治疗策略。
J Clin Med. 2025 Feb 28;14(5):1655. doi: 10.3390/jcm14051655.
2
Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?在新型疗法时代，自体挽救性移植在复发/难治性多发性骨髓瘤中是否仍有一席之地？
Ann Hematol. 2025 Mar;104(3):1735-1745. doi: 10.1007/s00277-025-06262-9. Epub 2025 Feb 26.
3
Are we there yet? CAR-T therapy in multiple myeloma.我们到了吗？嵌合抗原受体T细胞（CAR-T）疗法在多发性骨髓瘤中的应用
Br J Haematol. 2024 Dec;205(6):2175-2189. doi: 10.1111/bjh.19896. Epub 2024 Nov 19.
4
The efficacy and safety of second salvage autologous transplantation in myeloma patients.骨髓瘤患者二次挽救性自体移植的疗效和安全性。
Pathol Oncol Res. 2024 Jul 16;30:1611851. doi: 10.3389/pore.2024.1611851. eCollection 2024.
5
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.先进疗法时代复发难治性多发性骨髓瘤的管理：基于证据的常规临床实践建议
Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.
6
Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse.复发/难治性多发性骨髓瘤：可用疗法综述及骨髓瘤复发时的临床情况。
Curr Oncol. 2023 Feb 15;30(2):2322-2347. doi: 10.3390/curroncol30020179.
7
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.复发/难治性多发性骨髓瘤治疗中的差距和机遇：NCI 多发性骨髓瘤指导委员会的共识建议。
Blood Cancer J. 2022 Jun 29;12(6):98. doi: 10.1038/s41408-022-00695-5.
8
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.硼替佐米-沙利度胺-地塞米松-顺铂-多柔比星-环磷酰胺-依托泊苷作为挽救和桥接方案，用于复发或难治性多发性骨髓瘤患者造血干细胞移植前。
Intern Med. 2022 Nov 15;61(22):3329-3334. doi: 10.2169/internalmedicine.9097-21. Epub 2022 Apr 23.
9
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.多发性骨髓瘤门诊干细胞移植的可行性及预测住院的危险因素
J Clin Med. 2022 Mar 16;11(6):1640. doi: 10.3390/jcm11061640.
10
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.复发和/或难治性多发性骨髓瘤（MM）的变化态势：基础与争议
Biomark Res. 2022 Jan 9;10(1):1. doi: 10.1186/s40364-021-00344-2.

本文引用的文献

1
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.二次自体移植及来那度胺维持治疗对骨髓瘤患者首次自体移植后首次复发进行挽救治疗后的长期生存情况
Hematol Oncol. 2018 Apr;36(2):436-444. doi: 10.1002/hon.2490. Epub 2018 Jan 24.
2
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.自体移植治疗新诊断多发性骨髓瘤在新型诱导药物时代：系统评价和荟萃分析。
JAMA Oncol. 2018 Mar 1;4(3):343-350. doi: 10.1001/jamaoncol.2017.4600.
3
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.复发和难治性多发性骨髓瘤的治疗：新型药物、抗体、免疫疗法及其他。
Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16.
4
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
5
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
6
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
7
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.挽救性自体干细胞移植对复发多发性骨髓瘤患者总生存期的影响（英国血液与骨髓移植学会/英国骨髓瘤论坛骨髓瘤X复发[强化治疗]最终结果）：一项随机、开放标签的3期试验
Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7.
8
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.卡非佐米、来那度胺和地塞米松治疗复发多发性骨髓瘤。
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
9
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.自体移植治疗复发性多发性骨髓瘤患者：单中心 200 例经验。
Cancer. 2013 Jul 1;119(13):2438-46. doi: 10.1002/cncr.28104. Epub 2013 Apr 10.